e-learning
resources
ERJ
2018
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times
Arnaud Uguen
Source:
Eur Respir J, 51 (6) 1800602; 10.1183/13993003.00602-2018
Journal Issue:
June
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Arnaud Uguen. Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times. Eur Respir J, 51 (6) 1800602; 10.1183/13993003.00602-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives
Source: Eur Respir Rev 2011; 20: 45-52
Year: 2011
Utilisation of biomarker testing to guide therapy in non-small cell lung cancer in a regional lung cancer service
Source: International Congress 2018 – Genetics in chronic pulmonary diseases
Year: 2018
A cost minimisation comparison of five chemotherapy regimes for advanced nonsmall cell lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 431s
Year: 2003
The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer
Source: Eur Respir J 2013; 42: 1119-1133
Year: 2013
Biomarkers for non-small cell lung cancer (NSCLC) treatment: examples and unmet needs, a clinical perspective
Source: International Congress 2014 – From bench to bedside: biomarkers and biobanking for lung cancer in 2014
Year: 2014
Systematic evaluation of the efficacy–effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer
Source: Eur Respir J, 52 (6) 1801100; 10.1183/13993003.01100-2018
Year: 2018
Cost-effectiveness of
KRAS
,
EGFR
and
ALK
testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study
Source: Eur Respir J, 51 (3) 1701467; 10.1183/13993003.01467-2017
Year: 2018
Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer
Source: Eur Respir J 2006; 27: 895-901
Year: 2006
Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer
Source: Eur Respir J 2010; 36: 885-892
Year: 2010
Regular follow-up after curative resection of nonsmall cell lung cancer: a real benefit for patients?
Source: Eur Respir J 2002; 19: 464-468
Year: 2002
Reflex testing is crucial for treatment decisions in advanced non small cell lung cancer (NSCLC)
Source: International Congress 2017 – Chinese Programme 2017
Year: 2017
The optimal treatment of stage I nonsmall cell lung cancer in the era of SABR and modern day lung resections
Source: Eur Respir J, 56 (5) 2002595; 10.1183/13993003.02595-2020
Year: 2020
New treatment concepts in stage IV non-small cell lung cancer: personalised multidisciplinary approaches
Source: Virtual Congress 2021 – Thoracic oncology
Year: 2021
Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages
Source: Eur Respir Rev, 29 (155) 190052; 10.1183/16000617.0052-2019
Year: 2020
Modern profiling of advanced lung cancer at the primary diagnosis and during therapy
Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer
Year: 2018
Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies
Source: International Congress 2019 – State of the art session: Thoracic oncology
Year: 2019
Towards personalized treatment in non-small-cell lung carcinoma
Source: Virtual Congress 2020 – Management issues in thoracic oncology
Year: 2020
Delays in the diagnosis and treatment of non-small cell lung cancer
Source: Annual Congress 2010 - Quality management for lung cancer patients
Year: 2010
The evaluation of surgical results in pT0-pT1 non-small cell lung carcinoma after induction therapy
Source: Annual Congress 2011 - General thoracic surgery II
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept